Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Springworks Therapeutics Inc (SWTX)
Springworks Therapeutics Inc (SWTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,981,251
  • Shares Outstanding, K 62,579
  • Annual Sales, $ 0 K
  • Annual Income, $ -277,420 K
  • 60-Month Beta 0.78
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.05
Trade SWTX with:

Options Overview Details

View History
  • Implied Volatility 73.24% ( -2.60%)
  • Historical Volatility 102.51%
  • IV Percentile 41%
  • IV Rank 22.51%
  • IV High 128.76% on 11/27/23
  • IV Low 57.11% on 09/20/23
  • Put/Call Vol Ratio 0.73
  • Today's Volume 1,296
  • Volume Avg (30-Day) 862
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 8,697
  • Open Int (30-Day) 5,526

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -1.28
  • Number of Estimates 4
  • High Estimate -1.19
  • Low Estimate -1.34
  • Prior Year -1.19
  • Growth Rate Est. (year over year) -7.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.00 +60.78%
on 11/13/23
33.51 -13.63%
on 11/30/23
+4.63 (+19.05%)
since 11/03/23
3-Month
18.00 +60.78%
on 11/13/23
33.51 -13.63%
on 11/30/23
+0.74 (+2.62%)
since 09/05/23
52-Week
18.00 +60.78%
on 11/13/23
34.16 -15.28%
on 02/02/23
+4.69 (+19.34%)
since 12/05/22

Most Recent Stories

More News
SpringWorks Therapeutics: Q3 Earnings Snapshot

SpringWorks Therapeutics: Q3 Earnings Snapshot

SWTX : 28.94 (-8.59%)
SpringWorks Therapeutics: Q2 Earnings Snapshot

SpringWorks Therapeutics: Q2 Earnings Snapshot

SWTX : 28.94 (-8.59%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END

KTTA : 0.2950 (-4.84%)
DAWN : 12.08 (-0.66%)
SWTX : 28.94 (-8.59%)
VSTM : 7.24 (-3.34%)
KNTE : 2.23 (-0.45%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029

/PRNewswire/ -- Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue....

KTTA : 0.2950 (-4.84%)
SWTX : 28.94 (-8.59%)
DAWN : 12.08 (-0.66%)
VSTM : 7.24 (-3.34%)
KNTE : 2.23 (-0.45%)
SpringWorks Therapeutics: Q1 Earnings Snapshot

SpringWorks Therapeutics: Q1 Earnings Snapshot

SWTX : 28.94 (-8.59%)
BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s...

BGNE : 184.15 (+1.65%)
SWTX : 28.94 (-8.59%)
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023

MapKure, LLC, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1a/1b...

BGNE : 184.15 (+1.65%)
SWTX : 28.94 (-8.59%)
SpringWorks Therapeutics: Q4 Earnings Snapshot

SpringWorks Therapeutics: Q4 Earnings Snapshot

SWTX : 28.94 (-8.59%)
SpringWorks Therapeutics: Q3 Earnings Snapshot

SpringWorks Therapeutics: Q3 Earnings Snapshot

SWTX : 28.94 (-8.59%)
Here's Why You Should Consider Investing in JAZZ Stock Now

JAZZ's new drugs like Xywav, Rylaze and Zepzelca, along with the recently-acquired drugs, are expected to generate 65% of product revenues in 2022.

JAZZ : 121.49 (+0.03%)
AXSM : 68.59 (+1.72%)
SWTX : 28.94 (-8.59%)
HOWL : 2.70 (-1.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's product pipeline consists of Nirogacestat and Mirdametinib which are in clinical stage. SpringWorks Therapeutics...

See More

Key Turning Points

3rd Resistance Point 31.26
2nd Resistance Point 30.61
1st Resistance Point 29.77
Last Price 28.94
1st Support Level 28.28
2nd Support Level 27.63
3rd Support Level 26.79

See More

52-Week High 34.16
Last Price 28.94
Fibonacci 61.8% 27.99
Fibonacci 50% 26.08
Fibonacci 38.2% 24.17
52-Week Low 18.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar